International Pediatric Adrenocortical Tumor Registry
ConditionAdrenocortical Tumor
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 21
SponsorSt. Jude Children's Research Hospital
About this trial
This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumors in order to learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients with this rare disease, worldwide.
In addition, investigators at St. Jude Children's Research Hospital (SJCRH) plan to perform molecular studies of tumor cells aimed to clarify the role of the TP53 gene and other genetic pathways in these tumors. They aim to obtain relevant biological material from participants with adrenocortical tumor (ACT), their biological parents, and relatives for determination of the TP53 germline status, molecular studies of the TP53 gene, and other molecular pathways.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Stratum A: participant suspected or confirmed diagnosis of adrenocortical tumor (ACT)
Stratum R: relative of participant with ACT and TP53 mutation who has diagnosis of malignancy
Stratum P: biological parent of participant with ACT
Age ≤ 21 years old at diagnosis
Disqualifiers
None
Trial population
Age ≤ 21 years old at diagnosis of adrenocortical tumor. Relatives of the ACT patients of any age with a diagnosis of malignant tumor.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
9,999 Participants
are grouped into 1 trial groupGroup A: Participants
Trial outcomes
Primary outcomes
1
Collect demographic/medical information, detailed family history of cancer of children/adolescents with adrenocortical tumors, learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients
Time frame
Annually from diagnosis until no longer being followed, defined as up to 5 years from the date of last follow-upSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov